Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.74 |
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.61 |
| ▸ | LOXL2 | Q9Y4K0 | 3/20 | 0.48 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | ABAT | P80404 | 1/20 | 0.46 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL458481 | 0.92 | — | — | |
| Hydrochloric Acid SCHEMBL855336 | 0.89 | HRH3 (0.55) | HRH3TAAR1LOXL2CYP3A4IDO1 | |
| SCHEMBL2274647 | 0.86 | HRH3 (1.00) | HRH3TAAR1LOXL2CYP2A6ADRB2 | |
| SCHEMBL9305877 | 0.78 | CYP3A4 (0.44) | HRH3CYP3A4IDO1 | |
| SCHEMBL16848643 | 0.78 | CYP3A4 (0.44) | HRH3CYP3A4IDO1 | |
| SCHEMBL75931 | 0.76 | METAP2 (0.42) | CYP3A4IDO1 | |
| SCHEMBL2069523 | 0.76 | METAP2 (0.42) | CYP3A4IDO1 | |
| SCHEMBL66792 | 0.76 | METAP2 (0.42) | CYP3A4IDO1 | |
| SCHEMBL15828 | 0.76 | HRH3 (0.79) | HRH3TAAR1LOXL2ADRB2ABAT | |
| SCHEMBL3787138 | 0.76 | LOXL2 (0.83) | HRH3TAAR1LOXL2CYP2A6ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170335296-A1 | HBV RNASE H PURIFICATION AND ENZYME INHIBITORS | SAINT LOUIS UNIVERSITY (US) | 2017-11-23 | — | — | US | disclosed |
| CN-103570620-B | The luxuriant and rich with fragrance compounds of a kind of 1,12-imino group benzo [c], intermediate and preparation method and application | 昆山维信诺显示技术有限公司 | 2016-06-15 | — | — | CN | disclosed |
| CN-103570620-A | 1,12-iminobenzo[c]phenanthrene compound, intermediate, preparation method and application of compound | KUNSHAN VISIONOX DISPLAY TECH | 2014-02-12 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170335296-A1 | HBV RNASE H PURIFICATION AND ENZYME INHIBITORS | RNASEH1, RNASE1, RNASEL | HRH3 1045/4885TAAR1 4430/4885LOXL2 2865/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.